{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-25-000023","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2025-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.048834+00:00","generated_at":"2026-05-23T07:02:44.958063+00:00","sec_items":["2.02","2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Caribou cuts 32% workforce, discontinues lupus/AML trials, cash runway to H2 2027","bullets":["Workforce reduction of 47 employees (~32%), expected completion by Q2 2025.","Preliminary cash, equivalents & marketable securities of $212.5M as of March 31, 2025.","Discontinued GALLOP (lupus), AMpLify (AML) trials & preclinical research to focus on CB-010 & CB-011.","Estimated restructuring costs of $2.5-3.5M, primarily severance and trial wind-down.","Cash runway extended one year to H2 2027; CB-010 & CB-011 data readouts planned for H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-25-000023","json":"https://secwatch.observer/filing/0001619856-25-000023.json","markdown":"https://secwatch.observer/filing/0001619856-25-000023.md","text":"https://secwatch.observer/filing/0001619856-25-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000023/0001619856-25-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000023/crbu-20250424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T07:02:44.958063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}